Zymeworks (ZYME) Earns “Outperform” Rating from Raymond James
Raymond James restated their outperform rating on shares of Zymeworks (NYSE:ZYME) in a research report released on Thursday, BayStreet.CA reports. The brokerage currently has a $36.00 target price on the stock. Raymond James also issued estimates for Zymeworks’ Q2 2019 earnings at ($0.62) EPS and FY2019 earnings at ($2.63) EPS.
ZYME has been the topic of a number of other research reports. Zacks Investment Research raised Zymeworks from a hold rating to a strong-buy rating and set a $22.00 price objective on the stock in a report on Saturday, May 11th. Wells Fargo & Co upped their price objective on Zymeworks from $37.00 to $42.00 and gave the stock an outperform rating in a report on Monday, April 22nd. Canaccord Genuity set a $23.00 price objective on Zymeworks and gave the stock a buy rating in a report on Friday, May 3rd. Finally, ValuEngine lowered Zymeworks from a buy rating to a hold rating in a report on Saturday, May 18th. One equities research analyst has rated the stock with a hold rating, four have issued a buy rating and one has given a strong buy rating to the stock. The company has an average rating of Buy and a consensus target price of $28.40.
Shares of ZYME stock opened at $19.01 on Thursday. Zymeworks has a 1-year low of $10.72 and a 1-year high of $29.00. The firm has a market cap of $602.12 million, a P/E ratio of -15.09 and a beta of 1.58. The company has a current ratio of 6.76, a quick ratio of 6.76 and a debt-to-equity ratio of 0.04.
In other Zymeworks news, CFO Neil A. Klompas sold 8,308 shares of the company’s stock in a transaction on Monday, May 6th. The stock was sold at an average price of $19.23, for a total value of $159,762.84. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CEO Ali Tehrani sold 3,000 shares of the company’s stock in a transaction on Friday, March 29th. The shares were sold at an average price of $16.24, for a total value of $48,720.00. The disclosure for this sale can be found here. Insiders sold 12,108 shares of company stock worth $223,843 in the last three months. 4.80% of the stock is owned by corporate insiders.
A number of institutional investors have recently bought and sold shares of the business. Marshall Wace LLP acquired a new stake in Zymeworks in the first quarter valued at $902,000. FMR LLC boosted its stake in shares of Zymeworks by 331.4% during the first quarter. FMR LLC now owns 2,401,897 shares of the company’s stock valued at $38,863,000 after acquiring an additional 1,845,142 shares during the last quarter. Granite Investment Partners LLC boosted its stake in shares of Zymeworks by 87.8% during the first quarter. Granite Investment Partners LLC now owns 27,277 shares of the company’s stock valued at $441,000 after acquiring an additional 12,750 shares during the last quarter. Rubric Capital Management LP acquired a new stake in shares of Zymeworks during the first quarter valued at $2,626,000. Finally, Wells Fargo & Company MN boosted its stake in shares of Zymeworks by 34.1% during the first quarter. Wells Fargo & Company MN now owns 63,007 shares of the company’s stock valued at $1,019,000 after acquiring an additional 16,010 shares during the last quarter. 35.52% of the stock is currently owned by institutional investors.
Zymeworks Inc, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of bio-therapeutics for the treatment of cancer in Canada. The company's lead product candidates include ZW25, a bispecific antibody that is in Phase I clinical trial for the treatment of breast and gastric cancer; ZW49, a bispecific antibody-drug conjugate that is in preclinical stage for treating breast and gastric cancers, and solid tumors.
Featured Article: What is the definition of a trade war?
Receive News & Ratings for Zymeworks Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zymeworks and related companies with MarketBeat.com's FREE daily email newsletter.